MX2020002791A - Reduccion selectiva de proteinas. - Google Patents
Reduccion selectiva de proteinas.Info
- Publication number
- MX2020002791A MX2020002791A MX2020002791A MX2020002791A MX2020002791A MX 2020002791 A MX2020002791 A MX 2020002791A MX 2020002791 A MX2020002791 A MX 2020002791A MX 2020002791 A MX2020002791 A MX 2020002791A MX 2020002791 A MX2020002791 A MX 2020002791A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- engineered cysteine
- uncapped
- antibody molecules
- preparations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
- C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
- C07K1/086—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing sulfur
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Water Supply & Treatment (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona un método para hacer preparaciones de proteína de cisteína no coronada, que incluye las preparaciones del anticuerpo con cisteína diseñada no coronada. Los métodos incluyen, inter alia, poner en contacto un agente reductor con las moléculas del anticuerpo con cisteína diseñada, cada una de las moléculas del anticuerpo tiene al menos un residuo de cisteína diseñada coronada y al menos un enlace disulfuro intercadena y hacer reaccionar el agente reductor con las moléculas del anticuerpo bajo condiciones suficientes para eliminar la corona de los residuos de cisteína diseñada y formar subproducto coronados. El método también incluye eliminar el subproducto coronado durante la reacción de reducción. Sustancialmente todos los enlaces disulfuro intercadena presentes en las moléculas del anticuerpo antes de la reducción se retienen después de la reducción. Los conjugados de anticuerpo y los métodos para preparar los conjugados de anticuerpo utilizando las preparaciones del anticuerpo no coronado también se describen.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461938378P | 2014-02-11 | 2014-02-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020002791A true MX2020002791A (es) | 2020-07-22 |
Family
ID=53800577
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016010295A MX2016010295A (es) | 2014-02-11 | 2015-02-11 | Reduccion selectiva de proteinas. |
MX2020002791A MX2020002791A (es) | 2014-02-11 | 2016-08-09 | Reduccion selectiva de proteinas. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016010295A MX2016010295A (es) | 2014-02-11 | 2015-02-11 | Reduccion selectiva de proteinas. |
Country Status (9)
Country | Link |
---|---|
US (3) | US10464997B2 (es) |
EP (2) | EP3104881A4 (es) |
JP (3) | JP6713931B2 (es) |
KR (2) | KR102532137B1 (es) |
CN (3) | CN111187348A (es) |
CA (2) | CA3211226A1 (es) |
HK (1) | HK1231400A1 (es) |
MX (2) | MX2016010295A (es) |
WO (1) | WO2015123265A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112016004242A8 (pt) | 2013-08-28 | 2018-06-12 | Stemcentrx Inc | Métodos para conjugação sítio-específica de anticorpos e composições |
KR20160070191A (ko) | 2013-11-06 | 2016-06-17 | 스템센트알엑스 인코포레이티드 | 신규한 항-클라우딘 항체 및 사용 방법 |
BR112016013048A2 (pt) | 2013-12-12 | 2017-09-26 | Stemcentrx Inc | anticorpos anti-dpep3 e métodos de uso |
KR102532137B1 (ko) | 2014-02-11 | 2023-05-12 | 씨젠 인크. | 단백질의 선택적 환원 |
US10308721B2 (en) | 2014-02-21 | 2019-06-04 | Abbvie Stemcentrx Llc | Anti-DLL3 antibodies and drug conjugates for use in melanoma |
TW201617368A (zh) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗mfi2抗體及使用方法 |
US10842882B2 (en) * | 2015-03-09 | 2020-11-24 | Heidelberg Pharma Gmbh | Amatoxin-antibody conjugates |
PT3458100T (pt) | 2016-02-12 | 2020-08-05 | Byondis Bv | Redução seletiva de anticorpos modificados por cisteína |
AU2017261369A1 (en) * | 2016-05-06 | 2018-11-15 | Abbvie Stemcentrx Llc | Novel anti-TNFRSF21 antibodies and methods of use |
CA3041533A1 (en) * | 2016-11-07 | 2018-05-11 | Seattle Genetics, Inc. | Distribution of engineered-cysteine caps |
US20190381182A1 (en) * | 2017-02-08 | 2019-12-19 | Pfizer Inc. | Large scale production process for capped and un-capped antibody cysteines and their use in therapeutic protein conjugation |
CN107247144B (zh) * | 2017-05-16 | 2019-12-24 | 上海科华生物工程股份有限公司 | 一种预处理丙肝抗原的方法和检测试剂盒 |
RU2771310C2 (ru) * | 2017-05-23 | 2022-04-29 | Байондис Б. В. | Способ двойной конъюгации для получения конъюгатов антитело-лекарственное средство |
US20210346513A1 (en) * | 2017-08-04 | 2021-11-11 | Amgen Inc. | Method of conjugation of cys-mabs |
CN107746424A (zh) * | 2017-10-30 | 2018-03-02 | 上海药明生物技术有限公司 | 一种IgG4抗体的生物偶联方法 |
CN113423730B (zh) | 2019-02-15 | 2024-01-05 | 上海药明合联生物技术有限公司 | 用于制备具有改善的同质性的抗体-药物缀合物的方法 |
CN113189184B (zh) * | 2021-04-28 | 2022-09-09 | 浙江大学 | 含有半胱氨酸的毛细管凝胶电泳样品缓冲液 |
WO2023167564A1 (ko) * | 2022-03-04 | 2023-09-07 | 앱티스 주식회사 | 티올 반응성 에디티브를 이용한 항체-약물 컨쥬게이트의 제조 수율을 높이는 방법 |
CN114878728A (zh) * | 2022-05-06 | 2022-08-09 | 浙江大学 | 一种新型的抗体肽图检测还原方法 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US6111166A (en) | 1994-09-19 | 2000-08-29 | Medarex, Incorporated | Transgenic mice expressing human Fcα and β receptors |
GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US20030105017A1 (en) * | 2001-07-10 | 2003-06-05 | Gregory Conn | Purification of human Troponin I |
ES2556641T3 (es) | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
KR101438983B1 (ko) | 2003-11-06 | 2014-09-05 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
PL1791565T3 (pl) | 2004-09-23 | 2016-10-31 | Modyfikowane cysteiną przeciwciała i koniugaty | |
CA2605507C (en) | 2005-04-19 | 2016-06-28 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
GB0513852D0 (en) * | 2005-07-06 | 2005-08-10 | Celltech R&D Ltd | Biological products |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
EP3498289A1 (en) | 2005-07-07 | 2019-06-19 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
ES2374964T3 (es) | 2006-01-25 | 2012-02-23 | Sanofi | Agentes citotóxicos que comprenden nuevos derivados de tomaimicina. |
WO2008025020A2 (en) | 2006-08-25 | 2008-02-28 | Seattle Genetics, Inc. | Cd30 binding agents and uses thereof |
JP5727786B2 (ja) | 2007-10-19 | 2015-06-03 | シアトル ジェネティクス,インコーポレーテッド | Cd19結合性物質およびその使用 |
US20110033378A1 (en) * | 2008-01-18 | 2011-02-10 | Medlmmune, Llc. | Cysteine Engineered Antibodies For Site-Specific Conjugation |
PL2842575T3 (pl) | 2008-03-18 | 2018-02-28 | Seattle Genetics, Inc. | Koniugaty aurystatyny lek łącznik |
KR101984053B1 (ko) | 2009-02-05 | 2019-05-30 | 이뮤노젠 아이엔씨 | 신규한 벤조디아제핀 유도체 |
FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
EP2638066A4 (en) | 2010-11-09 | 2015-06-03 | Medimmune Llc | ANTIBODY EQUIPMENT FOR HOMOGENEOUS CONJUGATION |
WO2012112708A1 (en) | 2011-02-15 | 2012-08-23 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and methods of preparation |
US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
KR102532137B1 (ko) | 2014-02-11 | 2023-05-12 | 씨젠 인크. | 단백질의 선택적 환원 |
-
2015
- 2015-02-11 KR KR1020167022728A patent/KR102532137B1/ko active IP Right Grant
- 2015-02-11 CN CN202010117289.0A patent/CN111187348A/zh active Pending
- 2015-02-11 CA CA3211226A patent/CA3211226A1/en active Pending
- 2015-02-11 EP EP15749202.6A patent/EP3104881A4/en not_active Withdrawn
- 2015-02-11 CN CN202110215052.0A patent/CN112979786A/zh active Pending
- 2015-02-11 EP EP22202155.2A patent/EP4190809A1/en active Pending
- 2015-02-11 CA CA2938450A patent/CA2938450C/en active Active
- 2015-02-11 MX MX2016010295A patent/MX2016010295A/es active IP Right Grant
- 2015-02-11 US US15/117,254 patent/US10464997B2/en active Active
- 2015-02-11 WO PCT/US2015/015369 patent/WO2015123265A1/en active Application Filing
- 2015-02-11 KR KR1020237015699A patent/KR20230088389A/ko not_active Application Discontinuation
- 2015-02-11 CN CN201580008306.4A patent/CN106456725B9/zh active Active
- 2015-02-11 JP JP2016568485A patent/JP6713931B2/ja active Active
-
2016
- 2016-08-09 MX MX2020002791A patent/MX2020002791A/es unknown
-
2017
- 2017-05-22 HK HK17105164.0A patent/HK1231400A1/zh unknown
-
2019
- 2019-09-24 US US16/580,290 patent/US11667696B2/en active Active
-
2020
- 2020-05-29 JP JP2020094209A patent/JP2020143145A/ja not_active Withdrawn
-
2022
- 2022-08-05 JP JP2022125651A patent/JP2022153663A/ja active Pending
-
2023
- 2023-04-26 US US18/139,592 patent/US20230391848A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN106456725B (zh) | 2021-03-12 |
CN106456725B9 (zh) | 2022-08-09 |
WO2015123265A1 (en) | 2015-08-20 |
US20160347824A1 (en) | 2016-12-01 |
CN112979786A (zh) | 2021-06-18 |
KR20160136289A (ko) | 2016-11-29 |
US10464997B2 (en) | 2019-11-05 |
CA2938450C (en) | 2023-10-17 |
US20200115438A1 (en) | 2020-04-16 |
KR20230088389A (ko) | 2023-06-19 |
CA3211226A1 (en) | 2015-08-20 |
CN106456725A (zh) | 2017-02-22 |
CN111187348A (zh) | 2020-05-22 |
HK1231400A1 (zh) | 2017-12-22 |
EP3104881A4 (en) | 2017-09-27 |
JP2020143145A (ja) | 2020-09-10 |
CA2938450A1 (en) | 2015-08-20 |
KR102532137B1 (ko) | 2023-05-12 |
US20230391848A1 (en) | 2023-12-07 |
JP6713931B2 (ja) | 2020-06-24 |
JP2022153663A (ja) | 2022-10-12 |
MX2016010295A (es) | 2016-10-17 |
US11667696B2 (en) | 2023-06-06 |
EP4190809A1 (en) | 2023-06-07 |
EP3104881A1 (en) | 2016-12-21 |
JP2017506262A (ja) | 2017-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020002791A (es) | Reduccion selectiva de proteinas. | |
MX2023007045A (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos. | |
MX2022010324A (es) | Sitios especificos para modificar anticuerpos para hacer inmunoconjugados. | |
MX2023000818A (es) | Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos. | |
MX2018014387A (es) | Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos. | |
PE20170953A1 (es) | ANTICUERPOS ANTI-CD79b Y METODOS DE USO | |
PH12016501937A1 (en) | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage | |
MX2019012223A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
SA520412669B1 (ar) | تصنيع ذيفانات عصبية ناتجة عن معاودة الارتباط الجيني من المطثية الوشيقية | |
MX364908B (es) | Purificación de proteínas usando amortiguador bis-tris. | |
MX348071B (es) | Variantes de fc. | |
EA201691374A1 (ru) | Инсулин длительного действия и его применение | |
MX2015015188A (es) | Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab. | |
EA201290961A1 (ru) | Способы применения растворимого cd24 для лечения ревматоидного артрита | |
MX2017013333A (es) | Metodo para purificacion de proteina. | |
EA202090560A1 (ru) | Способ селективного извлечения элементов халькофильной группы | |
PH12016500403A1 (en) | An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof | |
MX2017008410A (es) | Reduccion selectiva de residuos cisteina en anticuerpos il-17. | |
PH12020550483A1 (en) | Anti-apoc3 antibodies and methods of use thereof | |
MX2020000037A (es) | Novedosa proteína terapéutica de fusión enzimática y uso de la misma. | |
PH12017502352A1 (en) | Cys80 conjugated immunoglobulins | |
UA118653C2 (uk) | Суперагоністи глікопротеїнового гормону тривалої дії | |
MY202141A (en) | Peptide mapping method for sequence identification of insulin & insulin analogues | |
MX2017000831A (es) | Cuantificacion de tnfr2 : fc plegada erroneamente. |